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NUCLEOZYMES necessary to have an all-RNA molecule to have catalytic 
activity. The ribozyme like molecules of the invention or 
“nucleozymes” have ribonucleotides or nucleic acid ana- RELATED APPLICATION 
This application is a divisional of application Ser. No. logues (hereinafter NAAs) at catalytically critical sites and 
071829,729, now U.S. Pat. No. 5,652,094, by Usman et al., s NAAs or deoxyribonucleotides at non-catalytically critical 
filed Jan. 31, 1992, entitled “Nucleozymes,” the whole of sites. The preferred nucleozymes have ribonucleotides at 
which is hereby incorporated by reference. catalytically critical sites. Nucleozymes have catalytic activ- 
This invention was made with government support under ity on the same substrates as their ribozyme counterparts. 
grant Numbers NGR-22-009-277 awarded by NASA, and The nucleozymes of the present invention thus essentially 
NIH-R37-CA04186 awarded by NIH. The government has 10 are modified ribozymes having at least a portion, or all, of 
certain rights in the invention. the ribonucleotides replaced with deoxyribonucleotides or 
NAAs. The nucleozymes are significantly more resistant to 
degradation than their all-RNA ribozyme counterparts 
because the chemicals or enzymes present in vivo do not 
polymers having catalytic activity. The invention also relates 15 recognize the nucleic acid internucleotide bonds, The resis- 
to methods of preparing and using nucleozymes. tance can be to either enzymatic or chemical degradation. 
Preferably, a majority of the ribonucleotides of the ribozyme 
are replaced with deoxyribonucleotides or NAAs. The sta- 
bility of the nuc~eozymes allows them to be useful as 
rendered inactive by enzymes, e,g, R N A ~ ~ ~ ,  present in vivo, 
The nucleozymes of the present invention are chimeric 
nucleic acid polymers having catalytic activity due to and 
preferably optimized by the presence of RNA or a NAA at 
a catalytically critical site. The present invention provides 
chemistry which allows synthesis of the chimeric polymers 
may be determined by varying the location of deoxyribo- 
nucleotides in a chimeric polymer and determining the 
mer’s ability to catalyze, 
The present invention pertains to a method for 
making a chimeric polymer. The polymers are made by 
under conditions to form substantially pure-protected phos- 
phoramidites or synthons of a single isomer. The protected 
phosphoramidites are coupled to each other forming a 
protected chimeric nucleic acid chain. The protecting groups 
conditions which completely deprotect the polymer. 
Problems 
aSsociated with a known Prior art method for Preparing 
chimeric RNNDNA Polymers (Perreault et al. Nature 
et al. J o ~ n a l  O f  the American 
Chemical Society 111:8531-33 (1989)). The prior art syn- 
thetic method for making chimeric Polymers had Problems 
with the migration of the protecting groups during the 
phosphitylating step, difficulty in removing the protecting 
removing the protecting groups in the deprotection step. The 
former problem results in the production of monomer units 
having protecting groups in an undesired position. The latter 
problem 
FIELD OF THE INVENTION 
This invention relates to nucleozymes, mixed nucleic acid 
BACKGROUND OF THE INVENTION 
Proteins were the only known catalysts of cellular reac- 
some instances, the folded structure of a ribozyme catalyses 
a cleavage reaction on another part of the same molecule 
(cis-reaction). In other instances (trans-reaction), the 
ribozyme may also act as a catalyst on another RNAor DNA 
molecule (substrate) by cleaving or ligating pieces of the 2s 
substrate without changing itself in the process. (Zaug et al. 
pp. 1532-39, 1987). 
tions until the discovery of RNA catalysts (ribozymes). In 20 therapeutic agents whereas ribozymes would be cleaved and 
Science, vol’ 231, PP’ 470-75, 1986; Science, vol’ 236, and the determination of catalytically critical sites, The sites 
A well-characterized example of a ribozyme is the self- 
menu themophila. An intron is an intervening sequence in 
a eukaryotic gene which does not encode a protein or in rare 
cases encodes a different protein. Introns are transcribed 
along with coding sequences (exons) to produce precursor 
the exons are ligated by RNA cleaving and splicing steps. 
The Group I intron or ribozyme of T. themophila catalyzes 
its own removal from the precursor RNA molecule. (Kruger 
et al. Cell 31:147-157, (1982); Zaug et al. (1986)). The 
transfer reactions. The ribozyme can act as a ribonuclease, 
ligase, phosphotransferase, acid phosphatase, polymerase 
and RNA restriction endonuclease (Zaug, A. J., et al., 
Science 231:47&475 (1986); Zaug, A. J., et al., Nature 
324:429-433 (1986); Zaug, A. J., et al., Biochemistry 45 344565-567 (1990); 
25:4478-4482 (1986); B ~ ~ ~ ,  M, D,,  et science 
239:1412-1416 (1988); Doudna et al., Nature 339:519-522 
(1989); all incorporated by reference herein). 
The <<hammerhea#> and “hairpin,, ribozymes also have 
344:565-567 (1990); Perreault e t  al, Biochemistry 
30:4020-25 (1991); Yang et al, Biochemistry 29:11156-60 
(1990); Chowrira et al, Biochemistvy 30:8518-22 (1991); 
Uhlenbeck Nature, 328:596-600 (1987)). The hammerhead 
Group I intron from the rRNA Of Tetrahy- 30 locations responsible for or related to the chimeric poly- 
RNA, The introns are removed from the precursor RNA and 35 phosphitylating protected Or units 
self-splicing ribozyme catalyzes a variety of phosphodiester 40 are removed from the chimeric acid under 
The method Of the Present invention 
been studied and described (Perreault et al,, Nature SO groups and has problems from the process Of 
in many cases, in 
ribozyme forms a stem loop secondary structure to form the 55 modification, b, phosphodiester linkage isomerization, and 
catalytically active molecule, The hairpin ribozyme has a to Of a amount Of protecting groups 
structure resembling a hairpin. 
Although ribozymes are intriguing molecules, their use 
for in vivo applications is limited if not precluded. The 
all-RNA molecules are susceptible to degradation from 
enzymes (RNAses) present in vivo. There presently is no 
intended site in an active form. 
on the polymer resulting in a non-functional polymer. The 
first problem was overcome in the present invention by 
selecting a catalyst capable of minimizing migration of 
60 protecting groups, e.g., a combination of 2,4,6-collidine and 
N-methylimidazole. The problem in removing the protecting 
the presence of ethanolic ammonia. way known to inventors for delivering such molecules to the 
groups was by deprotecting the mixed polymer in 
The present invention also pertains to methods of using 
65 the nucleozymes. The nucleozymes may be used to perform 
the same catalytic functions as their all-RNA ribozyme 
counterparts. For example, a nucleozyme may be used as a 
SUMMARY OF THE INVENTION 
The present invention is based on the discovery that 
ribozymes have catalytically critical sites and that it is not 
US 6,713,456 B1 
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ribonuclease, ligase, phosphotransferase, acid phosphatase, 
polymerase, or an RNArestriction endonuclease. The nucle- 
ozymes may be used to selectively cleave and ligate sub- 
strates by contacting the substrates with a nucleozyme such 
that the nucleozyme targets a specific sequence in the s 
substrate for cleavage or ligation, The nuc~eozymes may be 
used as polymerases to polymerize the production of an 
oligoribonucleotide or an oligodeoxyribonucleotide. The 
nucleozymes also may be used in place of antisense RNA 
technology. 10 clease. 
The nucleozymes also may be used as therapeutic agents 
introduced in vivo due to their resistance to chemical and 
example, in a method for treating a subject for a retrovirus 15 being 
associated disease, e.g., human immunodeficiency virus 
(HIV). The method involves administering a therapeutically 
effective amount of at least one nucleozyme to the subject 
such that the nucleozyme cleaves the RNA genome of the 
A ribozyme is an all-RNAcontaining molecule capable of 
being a biological catalyst. Ribozymes are art recognized 
and examples of such molecules include the “hammerhead” 
or “hairpin” ribozymes, 
The term “catalytic activity” is intended to include many 
types of catalysis. For example, the catalytic activity could 
be that of a ribonuclease, ligase, PhosPhotransferase acid, 
Phosphatase, Polymerase, and RNA restriction endonu- 
The term ((nucleic acid analogue” (NU) is intended to 
include analogues which are structurally similar to ribo- 
units in a polymer capable of hybridizing 
with DNA or RNA. The analogue may impart properties to 
a polymeric chain which differ from those of a nucleotide 
but the analogue is capable of being a monomer unit in a 
enzymatic degradation. The nucleozymes may be used, for nucleotides or deoxyribonucleotides and are capable of 
retrovirus rendering it inactive, A plurality of nucleozymes may impart resistance to chemi- 
also may be administered if it is desirable to target more than 20 cal Or enzymatic degradation to the chimeric polymer. 
polymeric chain. The 
NAAs may be selected for their structural conformation if a 
particular conformation is desired for the polymer. A NAA 
which is structurally similar to a ribonucleotide may be 
25 participating and/or attaining the desired catalytic activity. 
Preferably, if the NAAis positioned at a catalytically critical 
site it has a formula as depicted in Formulas I-IV below 
wherein X is a good coordinating ligand with divalent metal 
ions, eg., Mg+’. 
A nucleotide analogue may contain a heterocyclic ring as 
one sequence in the RNA genome. 
A nucleozyme may be provided in a pharmaceutical 
composition, The pharmaceutical composition would 
acceptable carrier. 
It is an object of the present invention to provide a 
nucleozyme capable of maintaining its catalytic properties in 
vivo. 
chimeric nucleic acid polymer having catalytic activity. 
include at least one nucleozyme and a pharmaceutically positioned at a catalytically site if the is capab1e Of 
It is an object of the present invention to provide a 30 
It is yet another object of the present invention to provide 
a method for preparing chimeric polymers which are free of 
depicted in the ‘-Iv Or may be as 
shown in The preferred ring 
protecting groups and undesired isomeric side products, 
a homogenous chimeric polymer. 
containing analogues of the present invention have three 
hydroxy substituents, alkoxy substituents or combinations It is yet another object of the present invention to provide 35 thereof, 
Formula (I) BRIEF DESCRIPTION OF THE DRAWINGS HO 
FIG. 1Adepicts a structure of a hammerhead nucleozyme. 4o 
FIG. 1B is a table listing nucleozymes of the present 
invention indicating the positions of ribonucleotides in the 
nucleozymes. The position designations correspond to the 
structure depicted in FIG. 1A. 
the cleavage of a 5’-32P-labeled RNA substrate. The desig- 
nation “RNA” is the all-RNA containing ribozyme and the 
nucleozymes are as abbreviated in FIG. 1B. 
FIG. 3 is a photograph of a gel demonstrating the cleavage 
of a radioactive RNA substrate by nucleozymes of the 
present invention containing methoxy substituted NAAs. 
The nucleozymes are abbreviated as in FIG. 1B. 
FIGS. 4A and 4B are graphs depicting the stability of 
nucleozymes compared to the stability of the all-RNA 
ribozyme counterpart after exposure to both RNAse A (4A) 
and a yeast cellular extract (4B). 
FIGS. 2A and 2B are photographs of a gel demonstrating 45 
55 
DETAILED DESCRIPTION 
The nucleozymes of the present invention have catalytic 60 
activity. Nucleozymes essentially are modified ribozymes 
preferably having at least one ribonucleotide or nucleic acid 
analogue ( N U )  at a catalytically critical site(s) and deox- 
yribonucleotides or NAAs at non-critical sites. The term 
“nucleozyme” is intended to include catalytic chimeric 65 
polymeric chains containing ribonucleotides and deoxyri- 
bonucleotides and/or nucleic acid analogues. 
” 
HO-R3 
I 
I 
R4 
HO 
Forumula (11) 
Formula (111) 
Formula (V) 
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-continued polymer may contain non-nucleotide spacer molecules 
along with its other nucleotide or analogue units. Examples 
of spacer molecules which may be used are described in 
Nielsen et al. Science, 254:1497-1500 (1991), the contents 
5 of which are expressly incorporated by reference. 
The analogues described above may be prepared using 
synthetic methods capable of attaching the desired moieties 
at the selected positions. Other possible analogues will be 
apparent to one of ordinary skill in the art. Deoxyribonucle- 
otides are readily available and may be purchased from a 
variety of sources. The alkyl substituted heterocyclic ring 
containing analogues may be synthesized by first reacting 
the moiety being modified with arabino triflates 
(trifluoromethane sulfonates) and second displacing the ara- 
bino triflates with an appropriate organotin compound 
selected on the basis of the desired moiety. A schematic of 
this reaction is depicted below: 
Formula (IV) 
10 
In the above is a base. The base nay be 
substituted or unsubstituted. Examples of bases include 
adenine, cytosine, guanine, uracil, 2-aminopurine, 
hypoxanthine, imidazole, 
15 
0 
II 
Ri-‘2-0- ~ 
D M T O y o ? B  D M T O w B  
R , S H - - ,  and R,-NH,-. The term “base” is art- 20 Sn-X  recognized and one of ordinary skill in the art would know 
which bases are useful in the present invention. X is selected 
from the group consisting of -OR,, F, -R,OH, -NH,, I 
RO -R,NH,, -Br, -R,Br and -R,F wherein R, is a lower 
alkyl group and R,-R4 are a lower alkyl hydrocarbon chains. zs 
I I  
RO X 
The term “lower alkyl” is intended to include from one to six This synthesis scheme may be used to prepare analogues 
carbons, more preferably one to three carbons and most wherein X is selected from the group consisting of -OR,, 
preferably a single carbon atom. For example, the most -R,OH, R2F, -RBr, and -RNH,. One of ordinary skill in 
preferred X is methoxy. the art would know how to synthesis the halogenated 
B may be protected during the synthesis process. The 30 analogues (X is -F or -Br) and the amino substituted 
protecting groups may be the conventional groups typically analogues (X is -NH,). These analogues may be synthe- 
used in oligonucleotide synthesis processes e.g., N6-benzoyl sized as described by Williams et al., Biochemistry, 
for adenine, N4-benzoyl for cytosine, N’-isobutyryl for 30:40014009 (1991), Doerr et al., J .  Org. Chem., 32:1462 
guanine, and N2-benzoyl for 2-aminopurine. Other useful (1967), Mengel et al. Angew. Chem., 90:557 (1978), or 
protecting groups include phenoxyacetyl (PAC) and 35 Coddington et al., J .  Org. Chem., 29:558 (1964), the con- 
t-butoxyacetyl (TAC). One of ordinary skill in the art would tents of each of the references are hereby expressly incor- 
know which protecting groups are appropriate for a particu- porated by reference. 
lar base. The acyclic nucleic acid analogues may be prepared by 
The NAAs capable of being positioned at a catalytically reacting a protected acyclic molecule with a diol. Reaction 
critical site may be determined by one of ordinary skill in the 40 processes which may be used are described in Durand et al., 
art using the following screening process. The catalytically NucZeicAcid Research, 18:6353 (1990); Seela et al., Nucleic 
critical sites of a particular ribozyme may be determined by Acid Research, 15:3113-3124 (1987); Cload et al., JACF, 
positioning deoxyribonucleotides(s) at various locations 113:6324-6326 (1991), the contents of each reference is 
within the ribozyme and evaluating the chimeric polymer’s hereby expressly incorporated by reference. 
catalytic activity. After determining the locations of the 45 The nucleozymes have catalytically critical site(s) at 
catalytically critical sites, NAAs may be substituted for the which a ribonucleotide or NAA is necessary for the nucle- 
deoxyribonucleotide(s) and the chimeric polymer’s catalytic ozyme to have the desired level of catalytic activity. The 
activity is again evaluated. If the NAA containing chimeric term “catalytically critical site” is intended to include sites 
polymer possesses catalytic activity then the NAAis suitable which, if altered from a ribonucleotide or a NAA to a 
for positioning at a catalytically critical site. SO deoxyribonucleotide, substantially reduces or even elimi- 
The term “synthon” is intended to include the fully nates catalytic activity. A substantial reduction in catalytic 
protected monomer units (phosphoramidites) used to activity would be that reduction which limits the usefulness 
assemble the nucleic acid analogues of a chimeric polymer of the nucleozyme as a catalyst in vitro or in vivo. The 
chain. The term “nucleic acid analogue” is used to describe catalytically critical sites may be determined for each nucle- 
the units when polymerized as part of a chimeric polymer ss ozyme. Catalytically critical sites can be determined by 
chain. preparing a variety of chimeric polymers using the chemical 
The term “chimeric polymer” is intended to include techniques described herein and comparing the catalytic 
polymers containing at least two different types of monomer activity of the chimeric test polymers. The catalytically 
units, e.g., RNA, DNA, or NAA. For example, a chimeric critical sites in the all-RNA containing ribozyme counter- 
polymer may include RNA/DNA, RNA/NAA, or DNA/ 60 parts are determined by selecting sites believed to be 
NAA polymeric chains. It should be understood that the involved in catalysis and inserting a deoxyribonucleotide at 
linkages between the building units of the polymeric chain the particular site. If the chimeric polymer does not have the 
may be linkages capable of bridging the units together for same or substantially the same catalytic activity as the 
either in vitro or in vivo. For example, the linkage may be all-RNAcounterpart, then the selected site is presumed to be 
a phosphorous containing linkage, e.g., phosphodiester or 65 a catalytically critical site. The hammerhead nucleozyme 
phosphothioate, or may be a nitrogen containing linkage, has four catalytically critical sites which are the G9, G12, 
e.g., amide. It should further be understood that the chimeric A13 and A29 positions for the sequence depicted in FIG. 1 .  
US 6,713,456 B3 
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The nucleozymes of the present invention are of a size The present invention also pertains to a method of making 
capable of being synthesized using the chemistry described a chimeric polymer. The method is similar to that described 
herein. Preferably, the nucleozymes have less than about 100 by Scaringe et al. to produce an all-RNApolymer. (Nucleics 
total building units, more preferably, less than about 80 Acid Research Vol. 18, No. 18, 5433-41 (1990)), the con- 
building units, even more preferably, less than about 70 s tents of which is expressly incorporated by reference. The 
building units, and most preferably less than about 50 method includes the steps of phosphitylating protected 
building units. Some nucleozymes may even have less than RNA, DNAor NAAunits under conditions which minimize 
about 20 building units. The preferred nucleozyme is mod- migration of the protecting group forming isomerically pure 
eled after the hammerhead ribozyme, the catalytic portion of protected phosphoramidites. The protected RNAor synthons 
which has 35 building units. The term “building unit” is i o  may have the desired moieties protected with the protecting 
intended to include ribonucleotides, deoxyribonucleotides, groups capable of surviving the phosphitylation and cou- 
or synthons. pling steps. Examples of such groups include conventional 
The nucleozymes of the present invention are modified DNA protecting groups such as 5’-O-DMT, N-Bz (Ade and 
ribozymes having at least a portion of the ribonucleotides Cyt), N-iBu (Gua), 0-cyanoethyl for phosphate, TB DMS 
replaced with deoxyribonucleotides or NAAs. The modified is for 2’-hydroxyl. 
ribozymes or nucleozymes are significantly more resistant to The term “isomerically pure protected phosphoramidites” 
degradation than the all-RNA counterparts. The degradation is intended to include phosphoramidite preparations free of 
may be either enzymatic or chemical degradation. The a substantial amount of undesired isomers of the phosphora- 
language “significantly more resistant to degradation” is that midites. A substantial amount is that amount which would 
resistance which allows the nucleozyme to remain largely 20 substantially interfere or impede with the preparation’s 
intact for an extended period of time relative to its all-RNA ability to be used in forming a mixed polymeric chain. For 
counterpart. Preferably it has a resistance which allows it to example, a consideration in the chemical synthesis of a 
be administered for in vivo applications. ribonucleotide phosphoramidite is contamination of the 
Resistance to enzymatic degradation may be resistance to desired 2’-O-protecting group-3’-0 phosphoramidite with 
enzymes present in vivo, e.g. RNAses such as RNAse A. zs the undesired 3’-O-protecting group-2’-O-phosphoramidite. 
FIGS. 4A and 4B are graphs depicting the relationship Syntheses performed with the latter lead to oligonucleotides 
between the percentage of the nucleozyme being intact at a having 5’-2’ linkages. Isomerically pure protected phos- 
particular RNAse A(F1G. 4A) or yeast cellular extract (FIG. phoramidites of the present invention lead to oligonucle- 
B) concentration. The data set forth in FIGS. 4Aand 4B was otides which are free of such undesired linkages. 
obtained using the following procedure. A sample of 0.001 30 The method of the present invention also involves cou- 
pmol of 5’ labeled nucleozyme or ribozyme was incubated pling the protected phosphoramidites together forming a 
with 0.5 mg of carrier TRNA in 50 mM Tris-HC1 (pH 7.4) protected chimeric polymeric chain. The coupling can be 
and 10 mM Mg+’ and different concentrations of RNAse A done using well-known chemical techniques known to one 
or yeast extract ten minutes for A, thirty minutes for extract. of ordinary skill in the art. Preferably the coupling is done 
The reactions were stopped by the addition of 20 mM EDTA 3s on an automated synthesizer. 
and loaded and analyzed on 15% PAGE in 7M urea. The After the chimeric polymeric chain is formed, the pro- 
yeast extract was prepared from a 1 ml culture of yeast strain tecting groups now can be removed from the chain under 
BWG2-9A grown to late-lag phase, harvested and washed conditions which completely deprotect the polymer. Also, 
with 25 mM sodium phosphate buffer (PH 7.8). The pellet nucleotide base modification and/or phosphodiester linkage 
was suspended in loop1 of the same buffer and sonicated for 40 isomerization of the chain now can be minimized during the 
20 seconds (60W). After centrifugation for five minutes in deprotection step. 
an Eppendorf centrifuge, the supernatant was used directly The prevention of migration of the protecting groups in 
after appropriate dilutions and incubations with the nucle- the phosphitylation step can be accomplished by phosphi- 
ozymes and the all-RNA ribozyme. tylating in the presence of a catalyst selected to minimize 
As shown in FIG. 4A, the nucleozymes were at least about 4s migration. An example of such a catalyst is the combination 
75% intact at an RNAse A log concentration of -1.5 and at of 2,4,6-collidine and N-methylimidazole. 
least about 80% intact at an RNAse A log concentration of The invention permits removal of the protecting groups in 
-2.5. Preferably, the nucleozyme is at least about 90% intact a manner that is complete and that minimizes nucleotide 
at both concentrations. The difference in stability between base modification and/or phosphodiester linkage isomeriza- 
the nucleozymes and ribozyme is even more apparent when SO tion. Complete removal of protecting groups includes sub- 
the enzyme is a yeast cellular extract (FIG. 4B). The stantially complete removal where a polymeric chain may 
nucleozymes were at least 90% intact at all of the tested have a small number of protecting groups still attached 
concentrations. which do not effect the polymeric chain’s intended catalytic 
The chemical degradation for purposes of this invention is function. The deprotection step is accomplished by depro- 
intended to include resistance to chemicals present in vivo ss tecting the polymer in the presence of an agent capable of 
and in vitro. The resistance may be to alkaline hydrolysis, minimizing such effects. An example of such an agent is 
e.g., sodium hydroxide and water. ethanolic ammonia. 
The preferred nucleozymes of the present invention are The method also allows the production of a homogeneous 
modified ribozymes having a majority of the ribonucleotides RNA/DNA polymer free of undesired isomeric products. 
replaced with deoxyribonucleotides or NAAs. At least one 60 The term “free” is intended to include substantially free 
of the units is a deoxyribonucleotide and preferably most of wherein a small amount of protecting groups or undesired 
the units are deoxyribonucleotides. The nucleozymes more isomers are present as long as the amount does not interfere 
preferably, have at least about 75%, even more preferably at or impede the polymer’s function. The minimization of 
least about 85%, most preferably at least about 90% of their nucleotide base modification is intended to include that 
ribonucleotides replaced with deoxyribonucleotides or 65 modification which would effect a polymeric chain’s 
NAAs. The nucleozyme also may be made up entirely of intended catalytic function. Minimizing phosphodiester 
NAAs or a combination of NAAs and deoxyribonucleotides. linkage isomerization, when used in connection with a 
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molecule, means preventing that degree of isomerization 
which would, adversely affect the molecule’s intended cata- 
lytic function. Minimizing phosphodiester linkage isomer- 
ization when used in connection with a preparation, means 
preventing that degree of isomerization which would sub- 
stantially affect the preparation’s abilities to be used for its 
intended catalytic functions. 
The present invention also pertains to methods for using 
the nucleozymes. The nucleozymes may be used for any 
method in which a ribozyme presently may be used. For 
example, the nucleozyme may be used to selectively cleave 
an RNA substrate or to ligate two pieces of RNA together. 
When cleaving a substrate, the RNA substrate is contacted 
with at least one nucleozyme which targets a specific 
sequence in the substrate for cleavage. A plurality of nucle- 
ozymes also may be used in a cleavage process. 
The nucleozymes of the present invention also may be 
used to polymerize an oligonucleotide molecule. The oligo- 
n u c l e o t i d e  m a y  c o n t a i n  r i b o n u c l e o t i d e s ,  
deoxyribonucleotides, and analogues of deoxy- or ribo- 
nucleotides. A template is contacted with a population of the 
appropriate nucleotide monomer units and a nucleozyme 
under conditions which allow an oligonucleotide comple- 
mentary to the template to form. The template preferably is 
attached to a support. 
The nucleozymes of the present invention also may be 
used for therapeutic methods due to their stability in vivo. 
The nucleozymes may be used, for example, to treat a 
subject for a retrovirus associated disease. A therapeutically 
effective amount of at least one nucleozyme is administered 
to a subject such that the nucleozyme(s) cleaves the RNA 
genome of the retrovirus or the viral mRNA rendering it 
inactive. 
A retrovirus associated disease is intended to include 
diseases involving retroviruses. Retroviruses have an RNA 
genome making them susceptible to cleavage by the at least 
one nucleozyme or the plurality of nucleozymes. An 
example of such a retrovirus associated disease is AIDS 
wherein the causative retrovirus is the human immunodefi- 
ciency virus (HIV). 
The term “subject” is intended to include living organisms 
susceptible to retroviruses, e.g., mammals. Examples of 
subjects include humans, cats, and rats. 
The language “therapeutically effective amount” is 
intended to include that amount capable of eliminating or 
significantly reducing the symptoms associated with retro- 
virus associated diseases. The amount may be determined on 
an individual basis and will be based, at least in part, on 
consideration of the severity of symptoms to be treated, the 
results sought and the size of the subject. Thus, a therapeu- 
tically effective amount may be determined by one of 
ordinary skill in the art employing such factors using no 
more than routine experimentation. 
The nucleozymes of the present invention also may be 
used in conjunction with or in place of antisense RNA 
technology. That is, to control the expression of a gene by 
targeting an appropriate mRNA. A nucleozyme may be 
selected based on its ability to target a particular mRNA 
sequence and subsequently an effective amount of the nucle- 
ozyme may be administered to a subject. The effective 
amount would be that amount necessary to target the RNA 
and control expression of a selected gene. 
The present invention also pertains to pharmaceutical 
compositions containing at least one nucleozyme and a 
pharmaceutically acceptable carrier. The language pharma- 
ceutically acceptable carrier is intended to include carriers 
capable of being co-administered with the nucleozyme(s) 
10 
while not adversely affecting the nucleozyme(s) catalytic 
activity. The carrier may be solid or liquid or a gel. Examples 
of liquid carriers include water, an aqueous solution of a 
non-toxic salt, e.g., sterile physiological saline solutions, or 
s aqueous solutions containing organic solvents, e.g., ethanol. 
Also suitable are emulsions, such as oil-in-water. Solid 
carriers may include nutritive carriers, e.g., sucrose or 
gelatin, or non-nutritive carriers, e.g., cellulose or talc. 
10 The Preferred Embodiment 
The preferred nucleozymes of the present invention are 
modeled after the “hammerhead” ribozyme. The moderate 
size of the catalytic hammerhead domains of RNA lends 
itself to chemical synthesis. As shown in FIG. lA,  the 
conserved hammerhead domain of around fifty ribonucle- 
otides found in naturally occurring RNA has been petitioned 
between a thirty-five unit catalytic fragment 10, the 
ribozyme, and a fourteen nucleotide substrate unit 12. 
The all-DNA analog of the hammerhead domain is inac- 
2o tive in catalysis. It was determined that nucleozymes con- 
taining as few as four ribonucleotides out of a total of thirty 
five nucleotides have catalytic activity. Active hammerhead 
nucleozymes require the presence of ribonucleotides in 
particular at four positions, particular the G9, G12, A13, and 
FIG. 1B is a table showing the chimeric polymers pre- 
pared along with the positions of ribonucleotides within the 
polymers. Nucleozymes are abbreviated as follows: DR and 
3o MR designate nucleozymes composed of predominantly 
deoxyribonucleotides and 2’-methoxynucleotides, respec- 
tively. The following number indicates the number of ribo- 
nucleotides and the final number refers to a particular 
combination of ribonucleotides. 
The all DNA analog of the hammerhead domain is 
inactive in catalysis. Several RNA/DNA mixed polymers 
appear as set forth and designated in the table of FIG. 1B. As 
shown in FIGS. 2A and 2B, the mixed polymer having 
ribonucleotides at positions 9, 10, 12, 13, 28, 29 and 30 of 
4o the ribozyme showed good catalytic activity (FIG. 2A). The 
nucleozyme containing the fewest ribonucleotides, DR4R3 
and DR4R2, showed at least some activity. In FIGS. 2A and 
2B, S indicates the mobility of the intact substrate and P, the 
product. RNAis the all-RNAribozyme and nucleozymes are 
45 abbreviated as in FIG. 1A. The presence or absence of the 
enzymatic fragment is indicated by + or -, respectively in 
FIG. 2A. Lane 1 is a control lacking the added catalytic 
fragment in FIG. 2A. Lane 1 in FIG. 2B is the 4.5 hour 
incubation of the substrate with neither Mg+’ nor nucle- 
ozyme and lane 2 is an incubation control in the presence of 
Mg+’ but no added nucleozyme. The samples were analyzed 
on 15% PAGE in 7M urea. 
FIG. 3 is a photograph showing the cleavage of radioac- 
tive substrates by OMe-nucleozymes. The S indicates the 
55 mobility of the intact substrate and P, the product. The 
reactions were performed as in FIG. 2 except that the 
incubations of the substrate were with the MR5R 
nucleozyme, for four hours and the (Mg+’)was varied. Lane 
1 contained no Mg+’, lane 2-10 mM, lane 3-20 mM, lane 
60 4-30 mM and lane 5-50 mM. The OMe-nucleozymes are 
nucleozymes having synthons which are methoxysubstituted 
in the 2‘ position. The nucleozymes designated MR contain 
all methoxysubstituted nucleozymes rather than deoxyribo- 
nucleotides. 
The catalytic activity of the nucleozymes was further 
evaluated by determining parameters including KM and K,,, 
for some of the kinetic reactions. In addition, the K, K, 
25 A29 positions shown in FIG. 1B. 
35 
65 
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and k3 of nucleozyme reactions were obtained to evaluate 
how extensive deoxyribonucleotide substitution effects 
Mg+' cofactor binding. A summary of these results is 
presented in Table 1 below. 
TABLE I 
Kinetic parameters of nucleozyme-catalyzed 
reaction? 
Substrate1 KM Kcat I& K3 KMg 
Nucleozyme @M) (llmin) @M) (llmin) (mM) 
RSIDR4R3 4.2 0.004 5 0.013 23 
RSIDRSR2 4.9 0.013 4 0.040 24 
RSIDR7R 4.5 0.067 5 0.21 24 
RSIRR 0.7 1.2 0.8 1.8 8.1 
aThe kinetic experiments were performed under the standard conditions of 
FIG. 2 with following differences: the final concentrations were: nucle- 
ozyme 0.05 ,uM, substrate from 0.5 ,uM to 5 ,uM; MgZf from 5 to SO mM 
and the reaction times from 30 min to 6 h at 30" C. Initial rates were 
determined from the first 10% of the reactions. The chronology of sub- 
strate and metal ion addition is currently not known. The values for Ks, 
k3 and KMg were, therefore, determined from the following random 
assembly model for ternary complex formation: 
The generalized reaction scheme used to determine the K 
values is depicted below. 
Ks 
E + S - E S  
+ + 
Mg2+ Mg2+ 
1$Mg2' 
K's k3 
EMg2' + S = ESMg2+ - P + E + Mg2+ 
The reaction scheme starts with the catalytic species, the 
substrate and the Mg+' cofactor, traversing a ternary com- 
plex and yielding a product. The apparent K's and K,s of 
the three nucleozymes are virtually identical and approxi- 
mately five times those of the all-RNA ribozyme acting on 
an RNA substrate. 
The chimeric polymers were synthesized as follows: 
Ribonucleotide, Deoxyribonucleotide, or 2'-Methoxy Ana- 
logue Phosphoramidite Synthesis and Purification 
Dry N-Acyl-5 '-O-DMT-2'-O-sily-ribonucleoside (10 
mmol, 1 eq) was dissolved in 30 ml dry THF in a 300 ml 
round bottom flask. 2,4,6-Collidine (75 mmol, 7.5 eq) was 
added followed by N-methylimidazole (5 mmol, 0.5 eq). 
(N,N-dispropylamino) (cyanoethyl) phosphonamidic chlo- 
ride (20 mmol, 2.0 eq [22 mmol, 2.2 eq in the case of 
guanosine or other nucleotide bases with reactive lactams]) 
was then added dropwise over 5 min at room temperature. 
The reaction was clear at the start but a white precipitate 
formed within 3 min (this is the collidine hydrochloride 
salt). The reaction was complete after 1-2 hour (determined 
by TLC). The reaction was then placed in an ice bath and 
diluted with 100 ml (1 volume) ethyl acetate. 150 ml 5% 
NaHCO, was added slowly (the first 10 ml over 5 minutes). 
(In the case of guanosine the reaction was first quenched 
with 5 ml of absolute ethanol). Heat was generated by the 
quenching of excess phosphitylating reagent. The mixture 
was then transferred to a separatory funnel and a second 
volume of ethyl acetate (100 ml) was added after first rinsing 
out the reaction flask. The aqueous phase was removed and 
the organic phase washed with saturated NaC1. The com- 
bined aqueous washes were back extracted with 50 ml. ethyl 
12 
acetate and the combined organic phases were dried over 
Na,SO,. The solvent was removed in vacuo yielding a 
viscous oil. Coevaporation (x5) with 50 ml toluene afforded 
the crude phosphoramidite as an offwhite foam or oil. 
s Excess phosphinic acid and collidine caused it to be oily. 
After leaving the amidite under high vacuum overnight, 
resuspension and rotovaping of the amidite with methylene 
chloride and ethyl acetate usually produced a foam. The 
phosphoramidites were further purified by silica gel chro- 
i o  matography yielding a white foam in 7 5 4 5 %  yields. This 
procedure was repeated for the preparation of the other 
desired phosphoramidites changing the initial protected 
nucleotide unit. The phosphoramidites were used to synthe- 
size the mixed polymers using automated synthesis tech- 
IS niques commonly used for the synthesis of deoxyribonucle- 
otides. 
Automated Synthesis of Mixed Polymers 
All syntheses were conducted on either a Gene Assembler 
Plus (Pharmacia), or a Cyclone (MilligeniBiosearch) syn- 
20 thesizer using standard protocols with an extended 12 min 
coupling step. A30 fold excess (15Opl of 0.1 M=15 mg, -15 
pmol) of the phosphoramidites and a 400 fold excess of 
tetrazole (400 pl of 0.5M=200 pmol) relative to CPG bound 
5'-hydroxyl was used in each coupling cycle. Synthesis scale 
2s was 0.5 pmol. Average coupling yields on the Gene Assem- 
bler Plus, monitored by an on-line colorimeter, were -99.0% 
and on the Cyclone 97-98%, determined by colorimetric 
quantitation of the trityl fractions. Reaction columns for 0.5 
pmol syntheses were Milligen/Biosearch 1.0 pmol columns. 
30 Oligonucleotide synthesis reagents: 1) for GA plus: detrity- 
lation solution was 2% TCA in ethylene dichloride; capping 
was performed with 20% N-Methyl imidazoyl in THF and 
10% acetic anhydride/lO% 2,6-lutidine in THF; oxidation 
solution was 0.02 MI,, 1% lutidine, 10% water in tHF. Baker 
35 Bio-Analyzed grade acetonitrile was further dried over 
activated 4 A molecular sieves. Tetrazole solution (0.5 M in 
acetonitrile was obtained from Applied Biosystems. 2) for 
Cyclone: all standard DNAsynthesis ancillary reagents were 
used. 
40 Deprotection of Mixed Polymers 
The CPG-bound mixed polymer was transferred from the 
synthesis column to a 4 ml glass screw top vial. 1 ml of 
ethanolic ammonia was added and heated at 55" C. for 16 hr. 
After cooling to -20" C., the ethanolic ammonia was 
45 removed from the CPG beads and the CPG was washed with 
0.5 ml of 50:50/ethanol:water which was-then added to the 
ethanolic ammonia. The combined supernatants containing 
the oligoribonucleotide were dried to a white powder. To 
remove the silyl protecting groups, the ammonia- 
SO deprotected mixed polymer was resuspended in 50 pl of 
50:50/ethanol:water and 600 pl of 1M TBAFRHF and left 
at room temperature for about 24 hr. The solution was then 
added directly to 10 ml of 0.1M TEAB and loaded onto a 
Qiagen 500 anion exchange cartridge (Qiagen Inc., Studio 
ss City, Calif.) prewashed with 10 pl of 0.5M TEAB, the 
nucleozyme was eluted with 7 ml of 2M TEAB and dried 
down to a white powder. 
Gel Purification of Fully Deprotected Mixed Polymers 
The oligomers were first checked by analytical PAGE 
60 (0.75 mmx20 cmx45 cm). 1 ODU of oligonucleotide in 5 pl 
H,O was added to 5 pl of deionized formamide and the total 
10 pl solution was loaded into a 1 cm wide lane. Following 
electrophoresis the gels were photographed by placing the 
gel over a fluorescent TLC plate and illuminating the gel 
65 with a UV lamp. The desired sequence was established 
according to electrophoretic mobility and purified by pre- 
parative electrophoresis using 1.5 mm thick gels with a 
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single 12 cm wide lane. After electrophoresis the desired 
tube, and covered with 50 mM NH,OAc pH 7.0. The tube 
was covered and kept at 37" C. OiN. The supernatant was 
then removed and the gel pieces washed with an additional ' 
1 ml of the extraction buffer. The combined washings were 
filtered through a 0.45 micron filter and loaded onto a 1 gram 
size Sep-Pak C18 cartridge (Waters-Millipore) prewashed 
with 5 ml each of acetonitrile, 50% acetonitrileiO.1M TEAB 10 
and 0.1M TEAB. After washing the cartridge with 5 ml of 
0.1 M TEAB, the RNA was eluted in 5 ml 35:35:30 
der. 
were prepared as described above. 
band was excised, cmshed, placed into a sterile 5 ml test acetonitrileimethanoliwater and dried down to a white POW- 
The mixed polymers set forth in the Table of FIG. 1B 
EQUIVALENTS 
in the art will be able to ascertain, using no 
more than routine experimentation, many equivalents of the 
specific embodiments of the invention described herein. 
These and all other equivalents are intended to be encom- 
passed by the following claims. 
Those 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 13 
<210> SEQ ID NO 1 
<211> LENGTH: 14 
<212> TYPE: RNA 
<213> ORGANISM: Artificial 
<2 2 0 > FEATURE : 
<223> OTHER INFORMATION: Example of a Nucleozyme target sequence 
<400> SEQUENCE: 1 
acggucucac gagc 
<210> SEQ ID NO 2 
<211> LENGTH: 35 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<2 2 0 > FEATURE : 
<223> OTHER INFORMATION: Description of Artificial Sequence: Nucleozyme 
<2 2 0 > FEATURE : 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (9)..(10) 
<223> OTHER INFORMATION: Ribonucleotide 
<2 2 0 > FEATURE : 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (12)..(13) 
<223> OTHER INFORMATION: Ribonucleotide 
<2 2 0 > FEATURE : 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (28)..(30) 
<223> OTHER INFORMATION: Ribonucleotide 
<400> SEQUENCE: 2 
gctcgtctga tgagtccgtg aggacgaaag accgt 
<210> SEQ ID NO 3 
<211> LENGTH: 35 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<2 2 0 > FEATURE : 
<223> OTHER INFORMATION: Description of Artificial Sequence: Nucleozyme 
<2 2 0 > FEATURE : 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (9)..(9) 
<223> OTHER INFORMATION: Ribonucleotide 
<2 2 0 > FEATURE : 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (13)..(13) 
<223> OTHER INFORMATION: Ribonucleotide 
14 
35 
<400> SEQUENCE: 3 
gctcgtctga tgagtccgtg aggacgaaag accgt 35 
<210> SEQ ID NO 4 
<211> LENGTH: 35 
<212> TYPE: DNA 
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- con t inued  
< 2 1 3 >  ORGANISM: A r t i f i c i a l  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence: N u c l e o z y m e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 9 ) . . ( 9 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 1 3 ) . . ( 1 3 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 2 9 ) . . ( 2 9 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<400>  SEQUENCE: 4 
g c t c g t c t g a  t g a g t c c g t g  aggacgaaag accgt  35 
< 2 1 0 >  S E Q  I D  NO 5 
< 2 1 1 >  LENGTH: 35 
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence: N u c l e o z y m e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 9 ) . . ( 9 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 1 3 ) . . ( 1 3 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 2 9 ) . . ( 3 0 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<400>  SEQUENCE: 5 
g c t c g t c t g a  t g a g t c c g t g  aggacgaaag accgt  35 
< 2 1 0 >  S E Q  I D  NO 6 
< 2 1 1 >  LENGTH: 35 
< 2 1 2 >  TYPE:  DNA 
< 2 1 3 >  ORGANISM: A r t i f i c i a l  
<220> FEATURE: 
< 2 2 3 >  OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence: N u c l e o z y m e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 9 ) . . ( 9 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 1 2 ) . . ( 1 3 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<220> FEATURE: 
< 2 2 1 >  NAME/KEY:  m i s c - f e a t u r e  
<222> LOCATION: ( 3 0 ) . . ( 3 0 )  
< 2 2 3 >  OTHER INFORMATION: R i b o n u c l e o t i d e  
<400>  SEQUENCE: 6 
g c t c g t c t g a  t g a g t c c g t g  aggacgaaag accgt  
< 2 1 0 >  
< 2 1 1 >  
< 2 1 2 >  
< 2 1 3 >  
<220> 
< 2 2 3 >  
<220> 
< 2 2 1 >  
<222> 
< 2 2 3 >  
35 
S E Q  I D  NO 7 
LENGTH: 35 
TYPE:  DNA 
ORGANISM: A r t i f i c i a l  
FEATURE : 
OTHER INFORMATION: D e s c r i p t i o n  of A r t i f i c i a l  Sequence: N u c l e o z y m e  
FEATURE : 
NAME/KEY:  m i s c - f e a t u r e  
LOCATION: ( 9 ) . . ( 9 )  
OTHER INFORMATION: R i b o n u c l e o t i d e  
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- con t inued  
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (12)..(13) 
<223> OTHER INFORMATION: Ribonucleotide 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (29)..(29) 
<223> OTHER INFORMATION: Ribonucleotide 
<400>  SEQUENCE: 7 
gctcgtctga tgagtccgtg aggacgaaag accgt 35 
<210> SEQ ID NO 8 
<211> LENGTH: 35 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Nucleozyme 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (9)..(9) 
<223> OTHER INFORMATION: Ribonucleotide 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (12)..(13) 
<223> OTHER INFORMATION: Ribonucleotide 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (29)..(30) 
<223> OTHER INFORMATION: Ribonucleotide 
<400>  SEQUENCE: 8 
gctcgtctga tgagtccgtg aggacgaaag accgt 
<210> 
<211> 
<212> 
<213> 
<220> 
<223> 
<220> 
<221> 
<222> 
<223> 
<220> 
<221> 
<222> 
<223> 
<220> 
<221> 
<222> 
<223> 
<400>  
35 
SEQ ID NO 9 
LENGTH: 35 
TYPE: DNA 
ORGANISM: Artificial 
FEATURE : 
OTHER INFORMATION: Description of Artificial Sequence: Nucleozyme 
FEATURE : 
NAME/KEY: misc-feature 
LOCATION: (9)..(10) 
OTHER INFORMATION: Ribonucleotide 
FEATURE : 
NAME/KEY: misc-feature 
LOCATION: (12)..(13) 
OTHER INFORMATION: Ribonucleotide 
FEATURE : 
NAME/KEY: misc-feature 
LOCATION: (30)..(30) 
OTHER INFORMATION: Ribonucleotide 
SEQUENCE: 9 
gctcgtctga tgagtccgtg aggacgaaag accgt 35 
<210> SEQ ID NO 10 
<211> LENGTH: 35 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Nucleozyme 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (9)..(10) 
<223> OTHER INFORMATION: Ribonucleotide 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (12)..(13) 
<223> OTHER INFORMATION: Ribonucleotide 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
<222> LOCATION: (29)..(30) 
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- con t inued  
<223> OTHER INFORMATION: Ribonucleotide 
<400>  SEQUENCE: 10 
gctcgtctga tgagtccgtg aggacgaaag accgt 
<210> 
<211> 
<212> 
<213> 
<220> 
<223> 
<220> 
<221> 
< 2 2 2 >  
<223> 
<220> 
<221> 
< 2 2 2 >  
<223> 
<400>  
35 
SEQ ID NO 11 
LENGTH: 35 
TYPE: DNA 
ORGANISM: Artificial 
FEATURE : 
OTHER INFORMATION: Description of Artificial Sequence: Nucleozyme 
FEATURE : 
NAME/KEY: misc-feature 
LOCATION: (9)..(9) 
OTHER INFORMATION: 2'-0-methyl-ribonucleotide derivative 
FEATURE : 
NAME/KEY: misc-feature 
LOCATION: (13)..(13) 
OTHER INFORMATION: 2'-0-methyl-ribonucleotide derivative 
SEQUENCE: 11 
gctcgtctga tgagtccgtg aggacgaaag accgt 35 
<210> SEQ ID NO 12 
<211> LENGTH: 35 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Nucleozyme 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
< 2 2 2 >  LOCATION: (9)..(9) 
<223> OTHER INFORMATION: Z'-O-methyl ribonucleotide derivative 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
< 2 2 2 >  LOCATION: (13)..(13) 
<223> OTHER INFORMATION: Z'-O-methyl ribonucleotide derivative 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
< 2 2 2 >  LOCATION: (29)..(29) 
<223> OTHER INFORMATION: Z'-O-methyl ribonucleotide derivative 
<400>  SEQUENCE: 12 
gctcgtctga tgagtccgtg aggacgaaag accgt 35 
<210> SEQ ID NO 13 
<211> LENGTH: 35 
<212> TYPE: DNA 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: Nucleozyme 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
< 2 2 2 >  LOCATION: (9)..(9) 
<223> OTHER INFORMATION: Z'-O-methyl ribonucleotide derivative 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
< 2 2 2 >  LOCATION: (12)..(13) 
<223> OTHER INFORMATION: Z'-O-methyl ribonucleotide derivative 
<220> FEATURE: 
<221> NAME/KEY: misc-feature 
< 2 2 2 >  LOCATION: (29)..(30) 
<223> OTHER INFORMATION: Z'-O-methyl ribonucleotide derivative 
<400>  SEQUENCE: 13 
gctcgtctga tgagtccgtg aggacgaaag accgt 35 
US 6,713,456 B1 
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What is claimed is: 
1. A pharmaceutical composition, comprising: 
at least one enzymatic nucleic acid molecule having a 
ribonucleotide at a catalytically critical site, at least one 
deoxyribonucleotide and at least one nucleic acid ana- 5 
log; and 
a nucleotide base-containing molecule having a ham- 
merhead motif which has the formula 3'-V-W-X-Y- 
Z-5', wherein V and Z are sequences which can base 
pair with said separate ribonucleic acid molecule and 
X is a sequence which can base pair inter se to form 
a hairpin; and wherein W comprises 3'-AbAAG-5, Y 
comprises two 3'-AGb-5'; wherein b represents a 
nucleotide having a 2'-OH group; and wherein at 
least one of the sugar moieties in said enzymatic 
nucleic acid molecule comprises, at its 2'-position, 
an analogue group other than hydroxyl alone, 
wherein said analogue group is not 2'-alkoxy or 
2'-halo, and does not comprise a nitrogen atom 
linked to the 2'-C, wherein said analogue group at 
each 2'-position may be the same or different; 
a pharmaceutically acceptable carrier. 
2. The pharmaceutical composition of claim 1, wherein 
said enzymatic nucleic acid molecule has enzymatic activity 
to cleave a separate ribonucleic acid molecule, and com- lo 
prises: 
a nucleotide base-containing molecule having a hammer- 
head motif which has the formula 3'-V-W-X-Y-Z-5', 
wherein V and Z are sequences which can base pair 1s 
with said separate ribonucleic acid molecule and X is a 
sequence which can base pair inter se to form a hairpin; 
and wherein W comprises 3'-AbAAG-5', y comprises 
two 3'-AGb-5'; wherein b represents a nucleotide hav- 
ing a 2'-OH group; 
and a pharmaceutica~~y acceptable carrier, 
4, A pharmaceutical composition, comprising: 
at least one enzymatic nucleic acid molecule having a 
ribonucleotide at a catalytically critical site and at least 
one deoxyribonucleotide or nucleic acid analog, and 
has catalytic activity to cleave a separate ribonucleic 
acid molecule, wherein said enzymatic nucleic acid 
molecule comprises 
a nucleotide base-containing molecule having a hairpin 
motif; and a pharmaceutically acceptable carrier. 
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and a pharmaceutically acceptable carrier. 
3. A pharmaceutical composition, comprising: 
at least one enzymatic nucleic acid molecule having a 
ribonucleotide at a catalytically critical site and at least 
one deoxyribonucleotide or nucleic acid analog and has zs 
enzymatic activity to cleave a separate ribonucleic acid 
molecule, comprising: * * * * *  
